Increased immune cell infiltration in patient-derived tumor explants treated with Traniplatin: an original Pt(iv) pro-drug based on Cisplatin and Tranilast

Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity...

Full description

Saved in:
Bibliographic Details
Published inChemical communications (Cambridge, England) Vol. 54; no. 60; pp. 8324 - 8327
Main Authors Lo Re, Daniele, Montagner, Diego, Tolan, Dina, Di Sanza, Claudio, Iglesias, Mar, Calon, Alexandre, Giralt, E
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 2018
Subjects
Cancer
Colon
Colorectal cancer
Cytotoxicity
Immune system
Infiltration
Platinum
Tumors
Online AccessGet full text

Cover

More Information
Summary:Elevated intra-tumoral immune infiltrate is associated with an improved prognosis in cancer of distinct origins. Traniplatin (TPT) is a novel platinum(iv) pro-drug based on Cisplatin (CDDP) and the marketed drug Tranilast. When compared in vitro to Cisplatin, TPT showed increased cytotoxic activity against colon and lung cancer cells but decreased activity against immune cells. In addition, TPT efficiency was evaluated in tumor explants derived from colorectal cancer samples from patients subjected to intended curative surgery. TPT induced strong intra-tumoral cytotoxic activity yet was associated with an elevated presence of immune cell infiltrate, suggesting a reduced cytotoxic activity against immune cells in colorectal cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-7345
1364-548X
DOI:10.1039/c8cc02071j